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ABSTRACT 
OBJECTIVE: To determine if Alitretinoin is a safe and effective alternative to current treatments 
in reducing the symptoms of Hand Eczema (HE) 
 
STUDY DESIGN: Review of all English language primary double-blind randomized controlled 
trial studies and an exploratory open-label case series from 1999-2009 
 
DATA SOURCES: An exploratory open-label case series comparing Alitretinoin at various 
dosages and randomized, controlled, double-blind clinical trials comparing Alitretinoin to 
placebo.  All sources were found using PubMed and Cochrane databases.  
 
OUTCOME MEASURED: The open-label case series was a pilot study where the treating 
physician measured erythema, papules/vesicles, desquamation, hyperkeratosis, rhagades and 
pruritus/pain on a 4-point scale from 0(no symptoms) to 4(severe symptoms).  Participants were 
evaluated monthly for 1-5 months, depending on how well each participant tolerated treatment.  
The randomized, controlled, double-blind clinical trials measured the modified Total Lesion 
Symptom Score (mTLSS), which measured the intensity of seven individual symptoms of 
chronic hand eczema: erythema, scaling, lichenification/hyperkeratosis, vesiculation, oedema, 
fissures, and pruritis/pain.  Participants of these studies were evaluated for each symptom with a 
score of 0(no signs or symptoms) to 3(severe symptoms) at baseline, twelve weeks, and twenty-
four weeks.   
 
RESULTS:  The open-label case series by Bollag found oral Alitretinoin to be very efficacious 
in the treatment of HE.  The two double-blind randomized controlled trials, by Ruzicka and 
Bissonnette, indicate significant results using oral Alitretinoin.  Results showed Alitretinoin 
induces clinically significant responses in a high percentage of patients with severe chronic hand 
eczema as both initial treatment as well as subsequent treatment for HE refractory to initial 
treatment with Alitretinoin.  Participants in all studies experienced only mild side effects from 
treatment, the most common of which was headache.   
 
CONCLUSIONS:  The results of these studies show that use of oral Alitretinoin given at 
individually well-tolerated doses (30-40 mg) induces clearing of HE in a substantial proportion 
of patients with severe disease refractory to standard corticosteroid therapy as well as HE 
refractory to treatment with a previous course of Alitretinoin.  Additionally, these studies show 
that Alitretinoin can be used safely as intermittent treatment for long-term management of HE.   
 
KEY WORDS: Alitretinoin, Hand Eczema 
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INTRODUCITON 
 Hand eczema (HE) is the most common dermatosis that affects the hands and many 
patients suffer from the condition chronically despite avoidance of causative agent(s).  The 
current treatment for HE is long-term use of topical corticosteroids.  However, even with this 
treatment patients experience decreased response over time, rebound flares, and overall lack of 
improvement.
1
  This paper evaluates two randomized controlled clinical trials that compare 
doses of 10 mg and 30 mg oral treatments of Alitretinoin to placebo.  Additionally evaluated is 
one open-label case series which compares multiple dosing regimens and tapers.  All studies 
were conducted in an effort to decrease symptoms of patients suffering from HE and improve 
long-term management.  
 HE affects 7-12% of the general population of Northern Europe and is estimated to affect 
an even higher percentage of the population in the United States.  Of the patients diagnosed with 
HE, 5-7% of them usually develop chronic hand eczema (CHE).
 
  There are many irritants, 
allergens, and exogenous factors that exacerbate HE, making it difficult to identify all triggers of 
the dermatosis.
 
 In severe cases, HE can cause occupational disability if the use of hands plays a 
key role in performing a job.  HE can also cause psycho-social disability as the condition can 
cause substantial disfiguring of the hands.
2
  In the Netherlands, annual costs of medical care, 
absenteeism, and disability pensions due to occupational skin disease in employees in 2001 were 
estimated at € 98.1 million (equivalent = $132 million).  There are currently no estimates for the 
number of healthcare visits per year for HE.
1-3
   
 A specific cause of HE is unknown but it is hypothesized to be multifactorial.  This 
condition is characterized by pruritis, which leads to erythema, vesiculation, scaling, 
lichenification, hyperkeratosis, blistering, fissures, and pain.  The long-term prognosis is 
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poor.  Current therapies include skin protection practices (i.e. gloves), lifestyle changes to avoid 
irritants, use of emollients, and topical corticosteroids.  Despite these treatments, many patients 
suffer chronically.  Because the efficacy of topical corticosteroids tends to decline over time, 
there is a great push to find a treatment that has consistent results with long-term use.  Retinoids 
are known to affect keratinization & inflammation.  Alitretinoin is a retinoid that binds to all six 
retinoid receptors in contrast to tretinoin, acitretin, and retinoic acid which have less binding 
capacity.  Previous studies have shown topical Alitretinoin (Panretin®) to be beneficial for AIDS 
patients with skin lesions from Kaposi sarcoma.  Current research is hopeful that Alitretinoin 
will have a similar beneficial effect on the skin for individuals suffering from HE.
1,4,5
   
OBJECTIVE: 
 The objective of this systematic review is to determine whether or not "Is Alitretinoin (9-
cis-retinoic acid) safe & effective for use in Hand Eczema?”  The hypothesis about the objective 
is that Alitretinoin given at well-tolerated doses is effective and an acceptable long-term 
treatment in clearing HE in patients with severe disease refractory to standard corticosteroid 
therapy. 
METHODS: 
 A detailed search was completed by the author, using search engines PubMed and 
Cochrane Database of Systematic Reviews.  The key words “Alitretinoin” and “Hand Eczema” 
were used in combination to search for English articles and all of the resulting articles were 
published in peer-review journals from 1999-2009.  The articles were selected based on the 
importance of outcomes to patient (Patient Oriented Evidence that Matters, or POEMS).  Studies 
that were included were those that were randomized, controlled, prospective, and were based on 
a patient-oriented outcome.  Excluded studies were those that used Alitretinoin as treatment for 
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diseases other than HE.  Randomized controlled trials (RCTs) were searched for those with a 
patient population between 16 and 75 y.o. with clinically diagnosed HE that was refractory to 
standard corticosteroid treatment.  Only RCTs that compared treatment groups receiving oral 
Alitretinoin compared to a placebo group were considered.  In addition, one exploratory open-
label case series compared multiple dosing regimens of Alitretinoin for tolerance and 
effectiveness.
5
  Under these criteria, two double-blind, randomized, placebo-controlled clinical 
trials and one open-label case series were identified and are included in this review.  Table 1 
includes demographics of the included studies.  The two RCT studies reported statistics based on 
numerical severity scores of CHE symptoms.  Statistics reported or used include p-values with a 
value of <0.05 being statistically significant.
 1-2,5
  
OUTCOMES MEASURED 
 Outcomes of the studies by Ruzicka and Bissonnette were measured by severity 
categorization, which corresponded to the intensity of HE symptoms.  Severity was defined 
according to the Physician Global Assessment (PGA) whereby seven symptoms are evaluated 
using the modified Total Lesion Symptom Score (mTLSS).  The mTLSS addressed erythema, 
scaling, lichenification/hyperkeratosis, vesiculation, edema, fissures, and pruritis/pain.  PGA 
categories were based on the mTLSS and ranged from “clear” to “severe.”  Among the seven 
total symptoms being addressed, qualifications were as follows:  Clear- no symptoms; 
undetectable, Almost Clear- at least one mild symptom/absent affecting <10% of hand surface, 
Mild- at least one mild symptom affecting <10% of hand surface, Moderate- at least one mild or 
moderate symptom affecting 10-30% of hand surface, Severe- at least one moderate or severe 
symptom affecting >30% of hand surface.  Participants were given a score for each of the seven 
symptoms that, when added together, determined the PGA score.  The scoring for each of the 
mTLSS symptoms rated on a scale from 0-3 where 0= no symptoms, 1=mild, 2=moderate, and 
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3=severe symptoms.  The criteria for the scoring of each symptom is as follows: Erythema 0-
absent, 1- faint, 2-prominent redness, 3-deep intense red color, Scaling 0-absent, 1- slight flaking 
over limited areas/mostly fine scales, 2- flaking over widespreasd areas(s)/coarser scales, 3- 
desquamation covering over 30% of hand with coarse thick scales, Lichenification/ 
Hyperkeratosis 0- absent, 1- mild thickening with exaggerated skin lines over limited areas, 2- 
palpable thickening over widespread areas, 3- prominent thickening over widespread areas with 
exaggeration of normal skin markings, Vesiculation 0- absent, 1- scattered vesicles affecting up 
to 10% of hand without erosion, 2- scattered or clustered vesicles affecting up to 30% of hand 
without erosion or excoriation, 3- high density of vesicles extending over large areas(s), or with 
erosion or excoriation, Edema  0- absent, 1- dermal swelling over less than 10% of hands, 2- 
definite dermal swelling over more than 10% of hand, 3- dermal swelling with skin induration 
over widespread areas(s), Fissures 0- absent, 1- cracked skin affecting a small area of the hand, 
cracked skin affecting multiple areas of the hand & causing pain, 3- one or more deep fissures 
and causing bleeding or severe pain, Pruritus/Pain 0- absent, 1- occasional, slight discomfort a 
few times per day, 2- intermittent, causing discomfort frequently during the day, 3- persistent or 
interfering with sleep.
1-2
 
 Bollag evaluated slightly different CHE symptoms: erythema, papules/vesicles, 
desquamation, hyperkeratosis, rhagades, and pruritus/pain, which were rated on a 0-4 point scale 
where 0- none, 1- slight, 2-moderate, 3-marked, 4-severe.  These scores were based on a 
subjective assessment by the treating physician on the correlation between Therapeutic Response 
(TR) and the Reduction of the Total Lesion/Symptom Score (rTLSS).  The rTLSS was recorded 
as a percentage that corresponded to a categorization of TR such that 0-20%- no therapeutic  
response, 21-40%- slight response, 41-60%- moderate response, 61-80%- good response, 81- 
100%- very good response.
5
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Table 1.  Characteristics of studies included in systematic review of the safety & effectiveness of 
Alitretinoin (9-cis-retinoic acid) for use in Hand Eczema 
Study Type #Pts Age
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventi
ons 
Bissonnette, 
CANADA 
 2009 
Double-
blind, 
placebo 
controlled, 
RCT 
117 49-
52 
BACH 
participants 
who rated as 
“clear” or 
“almost clear” 
hands 
according to 
PGA at 
termination of 
treatment, but 
then relapsed 
within 24 
weeks
immunosuppressants 
used within last 4 
weeks
drugs with potential 
interactions (i.e. 
systemic azoles, 
erythromycin, 
clarithromycin, 
simvastatin, St. 
John’s wort) within 
last 2 weeks,
use of concomitant 
retinoids (oral or 
topical to hands), 
vitamin supplements 
with > 2000 IU Vit. 
A
24 Alitretinoin 
10 mg or 30 
mg po QD x 
12-24 weeks 
  
Bollag, 
SWITZERLAND
1999 
Open label, 
Case Series 
38 16-
85 
Patients with 
CHE 
refractory to 
conventional 
therapy; 
emphasis on 
hyperkeratotic 
palmar 
eczema 
N/A 0 Alitretinoin 
20 mg or 40 
mg po x 1-5 
months 
Ruzicka, 
GERMANY 
2008 
Double-
blind, 
placebo 
controlled, 
prospective, 
multicentre 
RCT 
1032 18-
75 
18-75 y.o. and 
diagnosed 
with any type 
of severe hand 
eczema 
(CHE) of at 
least 6 months 
refractory to 
standard 
topical 
corticosteroid 
therapy
Diagnosis of 
psoriasis, atopic 
dermatitis treated 
with prescription 
drugs, active 
bacterial/fungal/viral 
infection of hands, 
or allergic contact 
dermatitis of hands 
with unavoidable 
exposure to allergen, 
or other skin 
diseases likely to 
interfere with the 
study
Use of concomitant 
retinoids (oral or 
topical to hands), 
vitamin supplements 
with > 2000 IU 
Vitamin A
273 Alitretinoin 
10 mg or 30 
mg po QD x 
up to 24 
weeks 
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RESULTS 
 
 This review includes double-blind, prospective, and exploratory open label studies 
analyzed with intention to treat with study participants being diagnosed with HE based on 
clinical criteria.  In the Bissonnette and Ruzicka studies, participants receiving Alitretinoin 
received 30 mg or 10 mg tablets by mouth while participants in the Bollag study received 20-40 
mg soft gelatin capsules of Alitretinoin by mouth.
1-2,5
  The Ruzicka study had the most 
participants with 409, 418, and 205 participants assigned to the 30 mg, 10 mg, and placebo 
groups respectively.  276 participants left the study due to insufficient response or adverse 
effects.  Therefore, 759 participants finished the study with 303 in the 30 mg goup, 319 in the 10 
mg group, and 137 in the placebo group.
2
  The Bissonnette study had the next greatest number of 
participants with 49, 21, and 47 in the 30 mg, 10 mg, and placebo groups respectively.  24 
participants were withdrawn due to adverse effects.
1
  The Bollag study had the least number of 
total participants with 38 entering and 38 completing the study.
5
 
 In the studies by Ruzicka and Bissonnette, participants were evaluated with mTLSS and 
PGA scores at baseline.  Participants were reevaluated at 12 and 24 weeks.  Assessment was 
carried out based on severity symptoms of each case of HE.  Symptoms tested consisted of 
erythema, scaling, lichenification/hyperkeratosis, vesiculation, edema, fissures, and pruritus/pain.  
Each symptom was rated on a scale from 0(absent symptoms) to 3(severe symptoms) with 21 
being the maximum number of points possible.
1-2
  The Bollag study evaluated symptoms of 
erythema, papules/vesicles, desquamation, hyperkeratosis, rhagades, and pruritus/pain.  
Symptoms were recorded as rTLSS on a scale from 0(absent symptoms) to 4(severe symptoms) 
for a maximum score of 24.
5
  The TLSS was converted to a percentage of participants who had 
improvement of symptoms (reduction in TLSS scores) from baseline scores for oral Alitretinoin 
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groups vs. placebo as shown in Table 2. 
Table 2. Median Percent Reduction in Total Lesion Symptom Score (mTLSS or rTLSS) 
from Baseline at each evaluation period for patients treated with oral Alitretinoin vs. 
Placebo for Symptoms of Hand Eczema  
Study Therapy Time 
  12 weeks 24 weeks 
Ruzicka 30 mg oral Alitretinoin * 75.0 
 10 mg oral Alitretinoin * 56.0 
 Placebo * 39.0 
Bissonnette 30 mg oral Alitretinoin 81.3 92.4  
 10 mg oral Alitretinoin 53.9 70.9 
 Placebo 33.4 42.9 
  16 weeks  
Bollag 20 or 40 mg oral Alitretinoin**  86.0 
*mTLSS scores not reported.  If, at 12 weeks, participant had a mTLSS resulting in a PGA of 
“clear” or “almost clear,” treatment was discontinued.  Remaining participants were evaluated at 
24 weeks.
2
 
**27 participants received 40 mg for entire treatment period; 3 participants took 40 mg for 1 
month and then 20 mg for the remainder of the study due to adverse effects;  8 participants began 
on 20 mg, 5 of whom continued this dose while 3 had dose increased to 40 mg after 1 month due 
to minimal response.
5
  
 
As shown in Table 2, percentage reduction of symptoms from baseline to the end of the studies 
proved to be substantial over all groups.  In the Ruzicka and Bissonnette studies, participants 
treated with 30 mg oral Alitreatinoin showed both early and clinically significant responses to 
treatment as compared to the 10 mg and placebo groups.  The slightly decreased percentage of 
the TLSS in the 10 mg oral Alitretinoin group shows that treatment success is greater at higher 
doses.  Additionally, both of these studies showed statistically significant decreases in TLSS 
among groups treated with 30 mg oral Alitretinoin with p-values of p<0.001.
1-2
  P-values were 
not reported for the Bollag study though the majority of participants (86%) had very successful 
responses to treatment.
5
 
 In order to analyze results, studies with “continuous” data were converted to 
“dichotomous” data.  This was the case for the Bollag study.  It was decided that participants 
with “Good” to “Very Good” improvement of symptoms would be considered significant change 
and that participants with “None, Slight, or Moderate” improvement would be considered 
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insignificant change.  In this way, the “experimental event rate” (EER) was determined as the 
percentage of participants who experienced “Good” or “Very Good “ improvement with 9-cis-
retinoic acid (RA).  The “control event rate” (CER) was determined to be the percentage of 
“Good or “Very Good” improvement with retinoids other than 9-cis-RA.   As for the studies by 
Ruzicka and Bissonnette, data was dichotomous already and therefore required no conversion.
1-2  
Using these numbers, a Relative Benefit Increase (RBI) and an Absolute Benefit Increase (ABI) 
could be calculated.  The Numbers Needed to Treat (NNT) of patients who needed to use 
Alitretinoin to improve their HE was determined from the ABI by subtracting the CER from the 
EER, and using the inverse result of 1/ABI.  The calculated analysis of outcomes and NNT in 
order to decrease the severity score of patients treated with oral Alitretinoin vs. placebo for HE 
can be seen in Table 3.    
Table 3. Analysis of Outcomes and NNT in Order to Decrease the Severity Score of 
Patients Treated with Alitretinoin for HE   
Study # completed 
study 
CER(%) EER(%) RBI(%) ABI(%) NNT(%) p value 
Ruzicka 759 17 48 182 31 4 <0.001  
Bissonnette 
  30 mg dose 
  10 mg dose 
93  
8 
10 
 
80 
48 
 
900 
380 
 
72 
38 
 
2 
3 
 
<0.001 
<0.004 
Bollag 38 5 89 1680 84 2 N/A 
 
 As can be seen in Table 3, the RBI was substantial in all three studies with the Bollag 
study showing, by far, the highest percent increase.  Despite the relatively large differences in 
RBI among the three studies, the NNT were quite similar, ranging from 2-4 patients. 
 In each of the studies, participants complained of a few adverse effects to treatment, 
likely associated with hypervitaminosis A syndrome.  The symptoms associated with this 
syndrome are headache, flush, conjunctivitis, mucocutaneous manifestations (chilitis, dry skin, 
dry lips), and musculoskeletal symptoms.  Adverse effects were found to be dose dependent.
1-2,5
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In the Ruzicka study, 276 participants left the study due to insufficient response or adverse 
effects while the Bissonnette study had 24 withdraw due to adverse effects.
1-2
  All participants 
that began the Bollag study completed it by decreasing Alitretinoin dose if patients experienced 
adverse effects or increasing the dose if patient showed signs of insufficient response.
5
 
DISCUSSION 
 The Randomized Controlled Trials and Open-Label Case Series in this review of the 
safety and efficacy of oral Alitretinoin in the treatment of HE showed that the medication can 
safely and effectively treat symptoms of the condition when given at maximal tolerated doses 
without causing adverse effects (30-40 mg).  Perhaps the Bollag study was most successful with 
highest RBI and lowest NNT because the study design allowed augmentation of the Alitretinoin 
depending on an individual’s response to a particular dose.  In this way, though doses varied, all 
participants were able to be treated until a successful outcome was reached.    
 Alitretinoin gel (Panretin®) was initially approved in the U.S. as topical treatment for 
AIDS-related Kaposi’s Sarcoma.  A current off-label use is for treatment of T-cell lymphoma.  It 
was not until August 2008 that Swiss manufacturer Basilea Pharmaceutica got approval to use 
their product Toctino®, an oral Alitretinoin, for treatment of HE.  Since then, it has been 
approved in other countries, including U.S., for HE treatment.  However, in 2010, the National 
Institute for Health and Clinical Excellence (NICE) made a recommendation that Toctino® be 
started only in patients severely affected by HE, and be discontinued as soon as adequate 
response is observed, or if HE remains severe for 12 weeks, or if inadequate response at 24 
weeks.  Effects of long-term use are unknown. 
6 
 The studies evaluated by this paper were limited by the novelty of Alitretinoin as a 
treatment for HE.  Though it has approved uses for other medical conditions, Alitretinoin is a 
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fairly new drug overall.  Literature on oral Alitretinoin is scarce.  To date, no research about oral 
Alitretinoin has been published in U.S.  Current publications are essentially pilot studies and are 
broadly directed.  As more is learned about the drug and its long-term effects, studies will be 
able to be more specifically structured.   
CONCLUSION 
 Alitretinoin is an effective treatment for HE when the condition is refractory or 
unresponsive to corticosteroid therapy.  The studies presented here show no severe adverse 
effects with use of Alitretinoin for up to a year, however, based on the most current literature and 
NIH recommendation, it is suspected that Alitretinoin may not be safe to use as long-term 
treatment for HE.  Until the safety and efficacy of oral Alitretinoin can be definitively 
determined in a long-term trial, future research could be directed at determining more 
specifically the triggering agents that exacerbate HE.  In this way, individuals who suffer from 
HE could be treated in a more preventative manner.  Avoiding triggers would likely prove to be 
safe practice and may very well be more effective than use of a long-term topical agent.   
If future studies prove to be as successful as those already completed, researchers will likely 
continue to get the funding they need to further explore this drug which holds much promise for 
the many sufferers of this physically painful, emotionally frustrating, and economically 
consuming chronic condition.   
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